oxonic acid has been researched along with Neutropenia in 99 studies
Oxonic Acid: Antagonist of urate oxidase.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 9.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan." | 9.22 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016) |
| "We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events." | 9.20 | Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015) |
| "S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC)." | 9.20 | Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M, 2015) |
| "We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)." | 9.16 | Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 9.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 9.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer." | 9.14 | Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 7.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| " A 66-year-old male treated with combined paclitaxel (PTX) and S-1 suffered from ARDS following neutropenia." | 7.74 | [Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007) |
| "Grade 3 neutropenia was common (35%)." | 6.90 | A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 6.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 6.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 5.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan." | 5.22 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016) |
| "We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events." | 5.20 | Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015) |
| "S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC)." | 5.20 | Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M, 2015) |
| "We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC)." | 5.17 | Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ( Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW, 2013) |
| "We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)." | 5.16 | Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 5.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 5.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer." | 5.14 | Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010) |
| "Patients were eligible for the study if they had histologically documented gastric adenocarcinoma previously treated with paclitaxel and cisplatin, age > or = 18 years, Eastern Clinical Oncology Group performance status < or =2, adequate organ function, and no evidence of gastrointestinal obstruction or passage disturbance." | 5.14 | Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Lee, SJ; Shim, HJ; Yoon, JY, 2009) |
| "A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 3.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| " A 66-year-old male treated with combined paclitaxel (PTX) and S-1 suffered from ARDS following neutropenia." | 3.74 | [Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
| "Grade 3 neutropenia was common (35%)." | 2.90 | A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019) |
| "Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown." | 2.90 | Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 2.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| "This phase I trial of preoperative S-1 in combination with oxaliplatin and radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis revealed that the recommended dose of oxaliplatin was 60 mg/m(2) weekly." | 2.80 | A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015) |
| "Paclitaxel was administered intravenously on day 1 at a dose of 120 mg/m(2), and oral S-1 was administered twice a day from days 1 to 7, followed by a 7-day drug-free interval." | 2.79 | Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. ( Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y, 2014) |
| "The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy." | 2.79 | Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014) |
| "Patients with gastric cancer with bulky lymph node metastasis along the coeliac artery and its branches and/or PAN metastasis received two or three 28-day cycles of S-1 plus cisplatin, followed by gastrectomy with D2 plus PAN dissection." | 2.79 | Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. ( Fukushima, N; Mizusawa, J; Nashimoto, A; Sasako, M; Tanaka, Y; Tsuburaya, A, 2014) |
| "Cediranib 20 mg/day in combination with cisplatin and S-1 or capecitabine was tolerable, with no new toxicities identified, and showed preliminary evidence of antitumour activity." | 2.77 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012) |
| "Paclitaxel (160 mg/m²) was administered by infusion for 3 h on the first day." | 2.76 | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. ( Goto, H; Haruta, J; Ina, K; Iwase, H; Kumada, T; Shimada, M; Shinoda, M; Sugihara, M; Tsuzuki, T, 2011) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| "Irinotecan (80 mg/m2) was infused on Days 1, 8, 22, and 29." | 2.76 | A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. ( Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K, 2011) |
| " Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle." | 2.75 | Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010) |
| "Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined." | 2.73 | A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. ( Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB, 2008) |
| "Paclitaxel was administered by intravenous drip infusion at a starting dose (level 1) of 50 mg/m2 on days 1, 8, and 15." | 2.72 | [A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer]. ( Doki, Y; Fujita, J; Fujiwara, Y; Kan, K; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, K; Yasuda, T, 2006) |
| "Grade 4 neutropenia was observed in one of the 59 patients (1." | 2.72 | [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. ( Kawahara, M; Yumine, K, 2006) |
| "He died of brain metastases." | 2.72 | [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]. ( Asou, H; Ichinose, Y; Maruyama, R; Okamoto, T; Suemitsu, R; Wataya, H, 2006) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 2.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Irinotecan was given intravenously over the course of 90 min on day 1 and S-1 was given orally from days 1 to 14 of a 21-day cycle." | 2.71 | Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H, 2003) |
| "Grade 4 neutropenia was observed in one of the 59 patients (1." | 2.70 | Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. ( Furuse, K; Hasegawa, K; Kawahara, M; Kudoh, S; Matsui, K; Niitani, H; Segawa, Y; Yoshimori, K, 2001) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
| "However, severe neutropenia is often observed (40%) during this therapy." | 1.48 | Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer. ( Kawachi, S; Kimura, M; Shinoda, Y; Usami, E; Yoshimura, T, 2018) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| "The chemotherapy regime was 80 mg/m(2) liposome-paclitaxel given on days 1, 8, 15 and 22, combined with S-1 60 mg (body surface area > 1." | 1.40 | Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer. ( Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z, 2014) |
| " Neutropenia, thrombocytopenia, nausea/vomiting and anorexia are the major treatment-related adverse events." | 1.38 | [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012) |
| " Thus, TS-1 and CPT-11 combination therapy has been effective for 17 months, suggesting that it is promising for long-term administration and survival to continue it perseveringly." | 1.33 | [A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy]. ( Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D, 2006) |
| "Grade 3 neutropenia was observed, but no other severe toxicities were noted." | 1.33 | [Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report]. ( Boku, N; Fukutomi, A; Yoshino, T, 2006) |
| "As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was conducted on an all-case basis." | 1.33 | [Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--]. ( Ito, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.02) | 18.2507 |
| 2000's | 37 (37.37) | 29.6817 |
| 2010's | 58 (58.59) | 24.3611 |
| 2020's | 2 (2.02) | 2.80 |
| Authors | Studies |
|---|---|
| Hirahara, N | 1 |
| Matsubara, T | 1 |
| Kaji, S | 1 |
| Yamamoto, T | 1 |
| Hyakudomi, R | 1 |
| Takai, K | 1 |
| Ishitobi, K | 1 |
| Uchida, Y | 1 |
| Tajima, Y | 1 |
| Kasai, T | 2 |
| Mori, K | 1 |
| Kishi, K | 1 |
| Kaburagi, T | 1 |
| Hosomi, Y | 1 |
| Imai, H | 2 |
| Yamada, Y | 4 |
| Yomota, M | 1 |
| Moriguchi, S | 1 |
| Seike, M | 1 |
| Minato, K | 1 |
| Gemma, A | 3 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 2 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 1 |
| Hamada, C | 1 |
| Okusaka, T | 3 |
| Ikari, T | 1 |
| Isayama, H | 3 |
| Furuse, J | 4 |
| Ishii, H | 2 |
| Nakai, Y | 3 |
| Imai, S | 2 |
| Okamura, S | 1 |
| Wang, F | 1 |
| Fan, QX | 1 |
| Wang, HH | 1 |
| Han, DM | 1 |
| Song, NS | 1 |
| Lu, H | 1 |
| Xu, R | 1 |
| Xu, J | 1 |
| Denda, T | 1 |
| Ikejiri, K | 1 |
| Shen, L | 2 |
| Toh, Y | 1 |
| Shimada, K | 4 |
| Kato, T | 1 |
| Sakai, K | 1 |
| Yamamoto, M | 1 |
| Mishima, H | 1 |
| Wang, J | 2 |
| Baba, H | 4 |
| Winther, SB | 1 |
| Bjerregaard, JK | 1 |
| Schonnemann, KR | 1 |
| Ejlsmark, MW | 1 |
| Krogh, M | 1 |
| Jensen, HA | 1 |
| Pfeiffer, P | 1 |
| Kawachi, S | 1 |
| Shinoda, Y | 1 |
| Kimura, M | 3 |
| Usami, E | 1 |
| Yoshimura, T | 1 |
| Nakachi, K | 1 |
| Konishi, M | 1 |
| Ikeda, M | 1 |
| Saiura, A | 1 |
| Sugiyama, M | 2 |
| Sakamoto, H | 1 |
| Shimamura, T | 1 |
| Ohta, T | 1 |
| Motoi, F | 1 |
| Satoi, S | 1 |
| Honda, G | 2 |
| Wada, K | 1 |
| Shinchi, H | 1 |
| Matsumoto, I | 1 |
| Sho, M | 1 |
| Tsuchida, A | 1 |
| Unno, M | 1 |
| Shigeyoshi, I | 1 |
| Misawa, K | 1 |
| Ito, S | 1 |
| Ito, Y | 3 |
| Komori, K | 1 |
| Abe, T | 1 |
| Senda, Y | 1 |
| Kinoshita, T | 1 |
| Uemura, N | 1 |
| Natsume, S | 1 |
| Oshiro, T | 1 |
| Higaki, E | 1 |
| Shimizu, Y | 2 |
| Sugawara, S | 1 |
| Nakagawa, K | 2 |
| Yamamoto, N | 2 |
| Nokihara, H | 1 |
| Ohe, Y | 1 |
| Nishio, M | 1 |
| Takahashi, T | 1 |
| Goto, K | 1 |
| Maemondo, M | 1 |
| Ichinose, Y | 4 |
| Seto, T | 2 |
| Sakai, H | 1 |
| Imamura, F | 1 |
| Shingyoji, M | 1 |
| Saka, H | 2 |
| Inoue, A | 1 |
| Takeda, K | 2 |
| Okamoto, I | 2 |
| Kiura, K | 1 |
| Morita, S | 4 |
| Tamura, T | 1 |
| Koizumi, W | 4 |
| Nishikawa, K | 2 |
| Gotoh, M | 2 |
| Fuse, N | 1 |
| Sugimoto, N | 2 |
| Nishina, T | 2 |
| Amagai, K | 1 |
| Chin, K | 1 |
| Niwa, Y | 1 |
| Tsuji, A | 4 |
| Imamura, H | 4 |
| Tsuda, M | 1 |
| Yasui, H | 4 |
| Fujii, H | 1 |
| Yamaguchi, K | 5 |
| Hironaka, S | 3 |
| Hyodo, I | 2 |
| Arai, H | 1 |
| Iwasa, S | 1 |
| Boku, N | 5 |
| Kawahira, M | 1 |
| Masuishi, T | 1 |
| Muro, K | 3 |
| Minashi, K | 1 |
| Fukuda, N | 1 |
| Takahari, D | 2 |
| Nakajima, TE | 3 |
| Iwase, H | 2 |
| Shimada, M | 2 |
| Tsuzuki, T | 2 |
| Hirashima, N | 1 |
| Okeya, M | 1 |
| Hibino, Y | 1 |
| Ryuge, N | 1 |
| Yokoi, M | 1 |
| Kida, Y | 1 |
| Kuno, T | 1 |
| Tanaka, Y | 3 |
| Kato, B | 1 |
| Esaki, M | 1 |
| Urata, N | 1 |
| Kato, E | 1 |
| Otsuka, H | 1 |
| Fujii, T | 1 |
| Toh, U | 1 |
| Iwakuma, N | 1 |
| Takahashi, R | 1 |
| Mishima, M | 1 |
| Takenaka, M | 1 |
| Kakuma, T | 1 |
| Tanaka, M | 2 |
| Shirouzu, K | 1 |
| Park, SR | 1 |
| Hong, YS | 2 |
| Lim, HS | 1 |
| Seong, MW | 1 |
| Kong, SY | 1 |
| Kim, SY | 1 |
| Park, YI | 1 |
| Jung, KH | 1 |
| Takahara, N | 1 |
| Sasaki, T | 6 |
| Hamada, T | 2 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Kogure, H | 2 |
| Sasahira, N | 2 |
| Hirano, K | 2 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 2 |
| Koike, K | 1 |
| Kaira, K | 3 |
| Tomizawa, Y | 2 |
| Yoshino, R | 1 |
| Yoshii, A | 1 |
| Matsuura, M | 1 |
| Iwasaki, Y | 2 |
| Koga, Y | 1 |
| Ono, A | 1 |
| Nishioka, M | 1 |
| Kamide, Y | 1 |
| Hisada, T | 3 |
| Ishizuka, T | 3 |
| Shirai, K | 1 |
| Ebara, T | 1 |
| Saitoh, J | 1 |
| Nakano, T | 1 |
| Sunaga, N | 3 |
| Chen, L | 1 |
| Chen, Q | 1 |
| Zhuang, Z | 1 |
| Zhang, Y | 1 |
| Tao, J | 1 |
| Shen, X | 1 |
| Chen, Z | 1 |
| Zhu, M | 1 |
| Wang, H | 1 |
| Sato, D | 1 |
| Kogashiwa, Y | 1 |
| Tsukahara, K | 2 |
| Yamauchi, K | 1 |
| Kohno, N | 2 |
| Tsuburaya, A | 2 |
| Mizusawa, J | 1 |
| Fukushima, N | 1 |
| Nashimoto, A | 1 |
| Sasako, M | 1 |
| Ohue, M | 1 |
| Hamaguchi, T | 2 |
| Sakai, D | 1 |
| Noura, S | 1 |
| Kinugasa, Y | 1 |
| Fujita, S | 1 |
| Shimada, Y | 3 |
| Saito, N | 1 |
| Moriya, Y | 1 |
| Yoshida, K | 3 |
| Kobayashi, M | 1 |
| Yoshino, S | 1 |
| Takahashi, M | 1 |
| Takiguchi, N | 1 |
| Tanabe, K | 2 |
| Takahashi, N | 1 |
| Tatsumoto, N | 1 |
| Hara, A | 1 |
| Fukushima, R | 1 |
| Nozaki, I | 1 |
| Kojima, H | 1 |
| Miyashita, Y | 1 |
| Oba, K | 1 |
| Buyse, M | 1 |
| Sakamoto, J | 3 |
| Zheng, Y | 2 |
| Fang, W | 1 |
| Mao, C | 1 |
| Qian, J | 1 |
| Zhao, P | 1 |
| Zhang, X | 1 |
| Jiang, H | 1 |
| Xu, N | 1 |
| Ishiwatari, H | 1 |
| Hayashi, T | 1 |
| Yoshida, M | 1 |
| Ono, M | 1 |
| Sato, T | 4 |
| Miyanishi, K | 2 |
| Sato, Y | 3 |
| Takimoto, R | 2 |
| Kobune, M | 2 |
| Kato, J | 2 |
| Nakamura, Y | 1 |
| Fukuda, M | 1 |
| Kitazaki, T | 1 |
| Nagashima, S | 1 |
| Takatani, H | 1 |
| Nakano, H | 1 |
| Nakatomi, K | 1 |
| Ikeda, T | 1 |
| Yamaguchi, H | 1 |
| Tsukamoto, K | 1 |
| Oka, M | 1 |
| Kohno, S | 1 |
| Takashima, T | 1 |
| Mukai, H | 1 |
| Hara, F | 1 |
| Matsubara, N | 1 |
| Saito, T | 1 |
| Takano, T | 1 |
| Park, Y | 1 |
| Toyama, T | 1 |
| Hozumi, Y | 1 |
| Tsurutani, J | 1 |
| Imoto, S | 1 |
| Watanabe, T | 1 |
| Sagara, Y | 1 |
| Nishimura, R | 1 |
| Shimozuma, K | 1 |
| Ohashi, Y | 2 |
| Moriwaki, T | 1 |
| Komatsu, Y | 4 |
| Machida, N | 1 |
| Bando, H | 1 |
| Esaki, T | 1 |
| Emi, Y | 3 |
| Sekikawa, T | 1 |
| Matsumoto, S | 3 |
| Takeuchi, M | 1 |
| Miyamoto, Y | 2 |
| Tanioka, H | 1 |
| Maekawa, S | 1 |
| Kawanaka, H | 1 |
| Kitazono, M | 1 |
| Oki, E | 3 |
| Murakami, H | 1 |
| Ogata, Y | 1 |
| Saeki, H | 1 |
| Shimokawa, M | 1 |
| Natsugoe, S | 2 |
| Akagi, Y | 1 |
| Maehara, Y | 4 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Kobayashi, S | 1 |
| Kurata, M | 1 |
| Okuda, Y | 1 |
| Sakamoto, K | 1 |
| Karasawa, K | 1 |
| Chang, T | 1 |
| Egawa, N | 1 |
| Kamisawa, T | 1 |
| Omuro, Y | 1 |
| Tsuruta, K | 1 |
| Tanahashi, T | 1 |
| Okumura, N | 1 |
| Matsuhashi, N | 1 |
| Yeo, W | 1 |
| Lam, KO | 1 |
| Law, AL | 1 |
| Lee, CC | 1 |
| Chiang, CL | 1 |
| Au, KH | 1 |
| Mo, FK | 1 |
| So, TH | 1 |
| Lam, KC | 1 |
| Ng, WT | 1 |
| Li, L | 1 |
| Arima, S | 1 |
| Shimizu, K | 3 |
| Okamoto, T | 2 |
| Toki, M | 1 |
| Suzuki, Y | 1 |
| Okano, N | 1 |
| Naruge, D | 1 |
| Kawai, K | 1 |
| Kobayashi, T | 1 |
| Kasuga, A | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Yanagitani, N | 2 |
| Aoki, H | 1 |
| Kawata, T | 1 |
| Utsugi, M | 2 |
| Mori, M | 2 |
| Zang, DY | 1 |
| Yang, DH | 1 |
| Kim, MJ | 2 |
| Jang, KM | 1 |
| Hwang, SW | 1 |
| Yoo, KS | 1 |
| Han, T | 1 |
| Kim, HY | 1 |
| Kim, HJ | 1 |
| Kwon, JH | 1 |
| Song, HH | 1 |
| Park, S | 1 |
| Jung, JY | 1 |
| Kim, HS | 2 |
| Kim, JH | 4 |
| Lee, SJ | 1 |
| Cho, SH | 1 |
| Yoon, JY | 1 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Shim, HJ | 1 |
| Chung, IJ | 1 |
| Park, I | 1 |
| Lee, JL | 4 |
| Ryu, MH | 2 |
| Chang, HM | 2 |
| Kim, TW | 4 |
| Sym, SJ | 1 |
| Lee, SS | 3 |
| Jang, G | 1 |
| Yoo, C | 1 |
| Bae, KS | 1 |
| Kang, YK | 2 |
| Oh, DY | 2 |
| Cha, Y | 1 |
| Choi, IS | 2 |
| Yoon, SY | 1 |
| Choi, IK | 1 |
| Oh, SC | 1 |
| Kim, CD | 1 |
| Kim, JS | 1 |
| Bang, YJ | 2 |
| Kim, YH | 1 |
| Iijima, H | 1 |
| Tsurumaki, H | 1 |
| Saito, R | 1 |
| Togawa, O | 1 |
| Toda, N | 1 |
| Yasuda, I | 1 |
| Hasebe, O | 1 |
| Maetani, I | 1 |
| Tsujino, T | 1 |
| Omata, M | 1 |
| Akiya, T | 1 |
| Sato, A | 1 |
| Sakuyama, T | 1 |
| Sasaki, E | 1 |
| Tomidokoro, T | 1 |
| Fujimori, M | 1 |
| Kikuchi, Y | 1 |
| Mine, T | 1 |
| Kurihara, M | 1 |
| Takiguchi, Y | 1 |
| Tada, Y | 1 |
| Kudoh, S | 3 |
| Hino, M | 1 |
| Yoshimori, K | 2 |
| Yoshimura, A | 1 |
| Nagao, K | 1 |
| Niitani, H | 2 |
| Yokoyama, T | 1 |
| Tokuhara, H | 1 |
| Egawa, T | 1 |
| Hashimoto, O | 1 |
| Seki, H | 1 |
| Koyanagi, K | 1 |
| Bessho, T | 1 |
| Takayama, T | 1 |
| Sagawa, T | 1 |
| Takahashi, Y | 1 |
| Ohnuma, H | 1 |
| Okubo, S | 1 |
| Shintani, N | 1 |
| Tanaka, S | 1 |
| Kida, M | 1 |
| Ohta, H | 1 |
| Hirata, K | 2 |
| Niitsu, Y | 1 |
| Yanagihara, K | 1 |
| Yoshimura, K | 1 |
| Niimi, M | 1 |
| Yasuda, H | 1 |
| Nishimura, T | 1 |
| Ishiguro, H | 1 |
| Kitano, T | 1 |
| Kanai, M | 1 |
| Misawa, A | 1 |
| Tada, H | 1 |
| Teramukai, S | 2 |
| Mio, T | 1 |
| Fukushima, M | 2 |
| Park, JH | 1 |
| Yoon, SN | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Jang, SJ | 1 |
| Lee, JS | 2 |
| Kim, JC | 1 |
| Nakayama, M | 1 |
| Hayakawa, K | 2 |
| Okamoto, M | 1 |
| Niibe, Y | 1 |
| Ishiyama, H | 1 |
| Kotani, S | 1 |
| Ozawa, H | 1 |
| Hatate, K | 1 |
| Onosato, W | 1 |
| Naito, M | 1 |
| Nakamura, T | 1 |
| Ihara, A | 1 |
| Okayasu, I | 1 |
| Yamashita, K | 1 |
| Watanabe, M | 2 |
| Nagase, T | 1 |
| Kanai, T | 1 |
| Nakagawa, M | 1 |
| Kumamoto, Y | 1 |
| Wada, O | 1 |
| Honda, T | 1 |
| Hoshino, G | 1 |
| Atsukawa, K | 1 |
| Sakaguchi, T | 1 |
| Shiba, T | 1 |
| Nonaka, T | 2 |
| Imajyo, K | 1 |
| Ogawa, Y | 1 |
| Chon, HJ | 1 |
| Rha, SY | 1 |
| Park, HS | 1 |
| Shin, SJ | 1 |
| Roh, JK | 1 |
| Noh, SH | 1 |
| Chung, HC | 1 |
| Jeung, HC | 1 |
| Nagai, H | 1 |
| Takamaru, N | 1 |
| Ohe, G | 1 |
| Uchida, D | 1 |
| Tamatani, T | 1 |
| Fujisawa, K | 1 |
| Iwamoto, S | 1 |
| Yuki, S | 3 |
| Sogabe, S | 2 |
| Fukushima, H | 2 |
| Iwanaga, I | 2 |
| Kudo, M | 3 |
| Tateyama, M | 3 |
| Meguro, T | 2 |
| Uebayashi, M | 1 |
| Saga, A | 1 |
| Sakata, Y | 3 |
| Asaka, M | 2 |
| Ina, K | 1 |
| Sugihara, M | 1 |
| Haruta, J | 1 |
| Shinoda, M | 1 |
| Kumada, T | 1 |
| Goto, H | 1 |
| Ueno, H | 1 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Ohkawa, S | 1 |
| Yokosuka, O | 1 |
| Tanaka, K | 1 |
| Moriyasu, F | 1 |
| Nakamori, S | 1 |
| Nakayama, N | 1 |
| Tanabe, S | 1 |
| Higuchi, K | 1 |
| Nishimura, K | 1 |
| Takagi, S | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Ishido, K | 1 |
| Nakatani, K | 1 |
| Naruke, A | 1 |
| Katada, C | 1 |
| Satoh, T | 1 |
| Hayashi, H | 1 |
| Taku, K | 1 |
| Shi, X | 1 |
| Brown, KH | 1 |
| Yamanaka, T | 2 |
| Katakami, N | 1 |
| Sawa, T | 1 |
| Nishimura, Y | 1 |
| Fukuoka, M | 1 |
| Nakatsumi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, M | 1 |
| Hatanaka, K | 1 |
| Miyagishima, T | 1 |
| Munakata, M | 2 |
| Kang, MJ | 1 |
| Ahn, S | 1 |
| Park, DH | 1 |
| Seo, DW | 1 |
| Lee, SK | 1 |
| Kim, MH | 1 |
| Kunisaki, C | 1 |
| Ono, HA | 1 |
| Hasegawa, S | 1 |
| Oshima, T | 1 |
| Fujii, S | 1 |
| Tokuhisa, M | 1 |
| Izumisawa, Y | 1 |
| Takagawa, R | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Makino, H | 1 |
| Akiyama, H | 1 |
| Endo, I | 1 |
| Kimura, Y | 2 |
| Yano, H | 1 |
| Fujitani, K | 2 |
| Imano, M | 2 |
| Tokunaga, Y | 1 |
| Matsuoka, M | 1 |
| Kurokawa, Y | 1 |
| Shimokawa, T | 2 |
| Takiuchi, H | 3 |
| Tsujinaka, T | 1 |
| Furukawa, H | 2 |
| Zhou, Y | 1 |
| Huang, J | 1 |
| Yang, L | 1 |
| Chi, Y | 1 |
| Qu, T | 1 |
| Lü, X | 1 |
| Wang, JW | 1 |
| Nishino, H | 1 |
| Shinozaki, T | 1 |
| Ishikawa, K | 1 |
| Tanaka, H | 1 |
| Ichimura, K | 1 |
| Goto, A | 2 |
| Arai, T | 1 |
| Ura, T | 1 |
| Shirao, K | 2 |
| Hino, S | 1 |
| Shintani, S | 1 |
| Hara, S | 1 |
| Hamakawa, H | 1 |
| Hirakawa, K | 2 |
| Nakata, B | 2 |
| Saji, S | 1 |
| Saeki, T | 2 |
| Takashima, S | 2 |
| Sano, M | 2 |
| Horikoshi, N | 2 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 2 |
| Taguchi, T | 2 |
| Nakazawa, M | 2 |
| Ohnishi, T | 1 |
| Chisoku, H | 1 |
| Katagiri, W | 1 |
| Doi, T | 1 |
| Takase, T | 1 |
| Yui, S | 1 |
| Miwa, Y | 1 |
| Fukuda, Y | 1 |
| Kishino, M | 1 |
| Yura, Y | 1 |
| Fujiwara, Y | 1 |
| Fujita, J | 1 |
| Kan, K | 1 |
| Takiguchi, S | 1 |
| Miyata, H | 1 |
| Yasuda, T | 1 |
| Doki, Y | 1 |
| Monden, M | 1 |
| Ito, K | 1 |
| Takahashi, I | 2 |
| Kakeji, Y | 2 |
| Tokunaga, E | 1 |
| Ushiro, S | 1 |
| Wataya, H | 2 |
| Asou, H | 1 |
| Maruyama, R | 1 |
| Suemitsu, R | 1 |
| Shitara, K | 1 |
| Kudou, T | 1 |
| Ohtsu, A | 1 |
| Wada, Y | 1 |
| Ukon, K | 1 |
| Hihara, J | 1 |
| Egashira, A | 1 |
| Morita, M | 1 |
| Eguchi, T | 1 |
| Fujii, M | 1 |
| Tahara, M | 1 |
| Yumine, K | 1 |
| Kawahara, M | 2 |
| Kawamura, S | 1 |
| Yamagishi, D | 1 |
| Tei, M | 1 |
| Sumi, Y | 1 |
| Shimada, E | 1 |
| Okumura, S | 1 |
| Yoshino, T | 1 |
| Fukutomi, A | 1 |
| Mitachi, Y | 1 |
| Yamamitsu, S | 1 |
| Takeuchi, T | 1 |
| Shirasaka, T | 1 |
| Ishiwata, R | 1 |
| Nagai, Y | 1 |
| Kang, HJ | 1 |
| Sohn, HJ | 1 |
| Kim, H | 1 |
| Hanada, N | 1 |
| Kusano, S | 1 |
| Hori, K | 1 |
| Momi, H | 1 |
| Kim, YJ | 1 |
| Im, SA | 1 |
| Kim, HG | 1 |
| Oh, SY | 1 |
| Lee, KW | 1 |
| Lee, SH | 1 |
| Kim, DW | 1 |
| Kim, TY | 1 |
| Kim, SW | 1 |
| Heo, DS | 1 |
| Yoon, YB | 1 |
| Goto, M | 1 |
| Imamoto, H | 1 |
| Ishida, H | 1 |
| Narahara, H | 1 |
| Nakajo, A | 1 |
| Hokita, S | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Etoh, T | 1 |
| Hamanoue, M | 1 |
| Maenohara, S | 1 |
| Iwashita, T | 1 |
| Komatsu, H | 1 |
| Satoh, K | 1 |
| Aridome, K | 1 |
| Nakano, S | 1 |
| Aikou, T | 1 |
| Toge, T | 1 |
| Aoyama, H | 1 |
| Ota, J | 1 |
| Noguchi, S | 1 |
| Inuyama, Y | 1 |
| Kida, A | 1 |
| Tsukuda, M | 1 |
| Satake, B | 1 |
| Furuse, K | 1 |
| Segawa, Y | 1 |
| Matsui, K | 1 |
| Hasegawa, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790] | Phase 2 | 53 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698] | Phase 2 | 62 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | ||
| Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer[NCT01375972] | Phase 2 | 92 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for oxonic acid and Neutropenia
| Article | Year |
|---|---|
S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2016 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Combination therapy with S-1 and CDDP for head and neck cancer].
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinom | 2006 |
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, N | 2006 |
[Clinical benefit of S-1 in metastatic breast cancer].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, | 2006 |
67 trials available for oxonic acid and Neutropenia
| Article | Year |
|---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2020 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1 | 2019 |
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dis | 2019 |
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons | 2019 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2015 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydro | 2013 |
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dr | 2013 |
Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Sch | 2013 |
Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2014 |
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A | 2015 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian Peo | 2014 |
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo | 2015 |
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dr | 2016 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Topics: Adenocarcinoma; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Fre | 2016 |
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor | 2015 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat | 2010 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatig | 2010 |
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2010 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; D | 2010 |
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2010 |
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
Topics: Aged; Aged, 80 and over; Anemia; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administr | 2010 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Su | 2011 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2011 |
A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviva | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Admi | 2012 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl | 2012 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2011 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
Topics: Aged; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2013 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dru | 2003 |
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2006 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dr | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2006 |
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C | 2006 |
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2006 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati | 1998 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce | 1998 |
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; | 2001 |
24 other studies available for oxonic acid and Neutropenia
| Article | Year |
|---|---|
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2018 |
Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2018 |
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Papillary; Carcino | 2018 |
[The Case of a Patient with Gastric Cancer Who Showed No Neutropenia Only When Using the Generic S-1 Adjuvant Chemotherapy Formulation].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Drugs, Generic; Fe | 2018 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug A | 2014 |
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Chemotherap | 2017 |
Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2009 |
[The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dise | 2009 |
[Analysis of four patients with advanced gastric cancer undergoing gastrectomy after pre-operative combination chemotherapy using docetaxel, cisplatin and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Co | 2002 |
[A case of advanced maxillary carcinoma with cervical lymph node metastases showing a complete response to the combination therapy of CDDP, TS-1 and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2004 |
[Preoperative chemotherapy with TS-1 and low dose cisplatin for oral squamous cell carcinoma patients--a preliminary study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
Topics: Antimetabolites, Antineoplastic; Capsules; Drug Administration Schedule; Drug Combinations; Drug Mon | 2006 |
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Dr | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; D | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; | 2006 |
Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2006 |
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; | 2007 |
[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2007 |